Summary.-The results of using a standard combination of cytotoxic agents in 27 cases of secondary liver cancer are reported. A brief review of the methods available for treating hepatic metastases from solid tumours, as opposed to lymphomata, is included. The response rate depends on the site of the primary lesion. It is suggested that in patients with mammary or colorectal primary tumours, combination chemotherapy represents an advance in treatment with an objective response rate of 730/% and 66% respectively in the 2 groups. The method requires no specialized equipment as neither grossly deranged liver enzymes nor jaundice are contra-indications to treatment, and toxicity is easily monitored and readily controlled.
Summary.-The results of using a standard combination of cytotoxic agents in 27 cases of secondary liver cancer are reported. A brief review of the methods available for treating hepatic metastases from solid tumours, as opposed to lymphomata, is included. The response rate depends on the site of the primary lesion. It is suggested that in patients with mammary or colorectal primary tumours, combination chemotherapy represents an advance in treatment with an objective response rate of 730/% and 66% respectively in the 2 groups. The method requires no specialized equipment as neither grossly deranged liver enzymes nor jaundice are contra-indications to treatment, and toxicity is easily monitored and readily controlled. CHEMOTHERAPEUTIC REGIMEN In 1971 Hanham, Newton and Westbury reported on 75 cases treated with quadruple chemotherapy using a modification of the regimen devised by Costanzi and Coltman (1969) . We have continued to use this regimen and this report concerns those patients in the first 150 treated by quadruple chemotherapy who had hepatic metastases.
Liver biopsy is not performed as a routine on patients suspected of having metastases, thus antemortem histological confirmation of liver involvement was not always available. Hepatic metastases were therefore diagnosed when 3 or more of the following were present: (1) Hepatomegaly; (2) raised alkaline phosphatase level; (3) raised aspartate aminotransferase (SGOT) level; (4) evidence of hepatic metastases on gamma scan.
Of the 150 patients reviewed, 27 had hepatic metastases on these criteria. This figure is lower than might be expected and this is largely explained by the high proportion of head and neck cancers.
Of these 27 patients, 11 had primaries in the breast, 9 had colorectal primaries and 7 had primaries in other sites (2 bronchus, 2 ovary, 2 melanoma and 1 stomach).
All patients were given quadruple chemotherapy in a 5-day course, with 3 weeks' lapse between courses. The drugs and their dosage are given in Table I . In patients who were jaundiced (Karnofsky and Burchenal, 1948 In America, Dillard (1969) and Flanagan and Foster (1967) have reported favourably on resection of hepatic metastases. The indications are limited, however, and Smith (1964) , reviewing his own figures in this country, stressed that " the most favourable case is the single large metastasis several years after resection Ingold et al. (1965) demonstrated the relatively low radiation tolerance of the liver to a dosage of 3000 rads given in 3 weeks, and this limits the use of external radiotherapy to the relief of pain in a few patients with advanced hepatic disease. Ariel, in 1960, first reported using radioactive isotopes in the treatment of hepatic secondaries. The isotopes were injected percutaneously into metastases whose location had been determined by gamma scanning. Later (Ariel, 1965) he used yttrium 90 attached to microspheres of ceramic /um in diameter which were injected intra-arterially. Both these techniques gave useful palliation. More recently, Ariel and Pack (1967) have compared the results of microsphere irradiation with chemotherapy for hepatic secondaries in a group of patients, the majority of whom had colorectal primaries; 27 % of cases achieved an objective response with chemotherapy, 320% with microsphere isotopes and 4700 when the 2 techniques were combined.
Following a prospective trial on patients with hepatic metastases from colorectal primary tumours, Rapoport and Burleson (1970) concluded that systemic 5-fluorouracil neither prolonged survival nor offered a high chance of response. Lahiri, Boileau and Hall (1971) , using oral 5-fluorouracil, showed good remission in a small series but only patients expected to survive a minimum of 3 months were considered for treatment.
Most chemotherapeutic regimens for hepatic secondaries have been by infusion techniques. The surgical aspects have been reviewed by Labelle et al. (1968) and XVatkins, Khazei and Nahra (1970) . Ariel and Pack (1965) concluded that there was no difference in response rates when catheters were located in the hepatic artery or the aorta, that methotrexate and 5-fluorouracil were equally effective, and that no superiority of an intermittent technique over continuous infusion could be demonstrated. In terms of patient response and survival the reports differ. Sullivan, Norcross and Watkins (1964), Sullivan and Zurek (1965) , Ariel and Pack (1965) , Brennan et al. (1963) and Burrows et al. (1967) all give optimistic results, in series with response rates of up to 6000, in patients with colorectal primaries. However, Lawrence (1965) concludes that the benefit is so small that it does not justify the discomfort and possible complications of the procedure.
The prognosis for patients with hepatic metastases is poor. Jaffe et al. (I1968) gave a median survival time of 75 days in their series, but they stressed that the site of the primary tumour influenced the prognosis and the median survival time for patients with colorectal primaries was 146 days. They concluded that to show an advance, treatment must increase the survival time of 5000 of patients with colorectal primary tumours to over 5 months. In a smaller series, Donegan, Harris and Spratt (1969) gave a median survival time of 4t months in untreated cases.
Our results in patients with primary breast tumours show an advance on all previous methods of treatment, with a mean survival of 13 months and 4000 of the patients still alive. Two cases are of particular interest in that their hepatic involvement presented with jaundice. This would normally be considered a contra-indication to most of the methods of treatment reviewed. It was considered, however, that a trial of chemotherapy was justified and at the time of commencing treatment their total serum bilirubin levels were 23 mg/100 ml and 13.8 mg/ 100 ml respectively. In both patients the serum bilirubin level was within normal limits after 2 courses of chemotherapy.
The results in the group with colorectal primaries are less dramatic although they do compare favourably with most of the treatments reviewed. It must be remembered, however, that we exercised no form of patient selection. Anyone with hepatic metastases, regardless of advanced disease, metastases elsewhere, grossly deranged liver function tests or jaundice, was treated. Furthermore, the treatment required no special surgical skills nor any specialized equipment.
Our results in patients whose primaries come from other sites must be considered inconclusive; the numbers involved were too small to draw any definite conclusions. All that can be said is that combination chemotherapy is probably worth trying in the otherwise untreatable case.
There was no objective evidence of hepatotoxicity from the treatment. The toxic effects seen were leucopenia, alopecia, nausea and vomiting. The patients had regular blood counts during treatment and the dosage was adjusted if leucopenia developed. The incidence of alopecia was reduced by using a scalp tourniquet. Nausea and vomiting were treated with routine antiemetics. In no case did toxicity necessitate stopping treatment.
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